<DOC>
	<DOCNO>NCT01742026</DOCNO>
	<brief_summary>ADVANCE THERAPY ASPERGILLOSIS INVASIVE BY PCR DETECTION</brief_summary>
	<brief_title>Aspergillus PCR Early Detection High Risk Oncohematological Patients</brief_title>
	<detailed_description>ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>Signature inform consent participate study . Adult patient ( &gt; 18 year ) , diagnose acute myelogenous leukemia myelodysplastic syndrome chemotherapy ( CT ) intensive , admit undergo allogeneic hematopoietic progenitor cell , transplantation graft versus host disease . The patient include protocol start chemotherapy conditioning therapy reflect another section . Employment antifungal prophylaxis ( 30 day prior inclusion ) triazole / polyene activity Aspergillus ( itraconazole , voriconazole , posaconazole , amphotericin B inhalation ) . Use systemic antifungal activity Aspergillus ( amphotericin , terbinafine , flucytosine , echinocandins , etc. ) . Therefore Fluconazole prophylaxis exclusively . Background IFI proven / probable prior Probable IFI / test time inclusion study . Exclusion cause lack compliance inclusion criterion . Patients lack follow biweekly galactomannan PCR . Have bacterial infection properly treat controlled start empirical antifungal treatment ( accord definition give ) . And finally neutropenia short duration create significant risk IFI . This information know logically include patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>High risk aspergillosis infection patient</keyword>
</DOC>